Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M
Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Gut. 1998 Sep;43(3):317-21. doi: 10.1136/gut.43.3.317.
Clarithromycin is one of the most important antibiotics for Helicobacter pylori eradication. However, 5-10% of strains are reported to be resistant. It has been shown that one point mutation in the 23S rRNA gene is associated with resistance to clarithromycin.
To establish a polymerase chain reaction (PCR) system which amplifies a segment of the 23S rRNA gene containing the mutation points with primers specific for H pylori, so that H pylori infection and the mutation associated with clarithromycin resistance can be examined simultaneously.
To detect H pylori infection and the mutation simultaneously, primers specific for the H pylori 23S rRNA gene were designed based on sequence conservation among H pylori strains and sequence specificity as compared with other bacteria. DNA from 57 cultured strains and from 39 gastric juice samples was amplified in the seminested 23S rRNA PCR. Clinical applicability was evaluated in 85 patients.
DNA samples from 57 cultured strains were all amplified. The novel assay and the urease A PCR agreed in 37/39 gastric juice samples with no false positives. The assay did not amplify the DNA of bacteria other than H pylori. Eight of 85 samples had the mutation before treatment. In clarithromycin based treatment, eradication was achieved in 2/5 (40%) with the mutation and 29/34 (85%) without the mutation.
The assay using gastric juice is quick (within 12 hours) and non-invasive (endoscopy not required), enabling rapid initiation of appropriate antibiotic treatment.
克拉霉素是根除幽门螺杆菌最重要的抗生素之一。然而,据报道有5%-10%的菌株具有耐药性。研究表明,23S rRNA基因中的一个点突变与对克拉霉素的耐药性有关。
建立一种聚合酶链反应(PCR)系统,该系统使用针对幽门螺杆菌的引物扩增包含突变点的23S rRNA基因片段,以便能够同时检测幽门螺杆菌感染和与克拉霉素耐药性相关的突变。
为了同时检测幽门螺杆菌感染和突变,基于幽门螺杆菌菌株间的序列保守性以及与其他细菌相比的序列特异性,设计了针对幽门螺杆菌23S rRNA基因的引物。在半巢式23S rRNA PCR中扩增了来自57株培养菌株和39份胃液样本的DNA。对85例患者评估了临床适用性。
来自57株培养菌株的DNA样本均被扩增。新检测方法与脲酶A PCR在39份胃液样本中的37份结果一致,无假阳性。该检测方法未扩增幽门螺杆菌以外的细菌DNA。85份样本中有8份在治疗前存在该突变。在基于克拉霉素的治疗中,有突变的患者中2/5(40%)根除成功,无突变的患者中29/34(85%)根除成功。
使用胃液的检测方法快速(12小时内)且非侵入性(无需内镜检查),能够迅速开始适当的抗生素治疗。